Alafi Capital's $2.8M Private Placement Purchase Lifts CalciMedica Stake to 17.1%

summarizeSummary

Alafi Capital invested $2.8 million in CalciMedica's private placement, buying 3.5 million shares at $0.8033 each and raising its stake to 17.1%. The move is part of a broader $49 million financing and follows other insider buying, underscoring confidence in the company's clinical and financial momentum.

check_boxKey Events · Ownership and Investor Activity · CALC

• Alafi Capital Invests $2.8M

  Through the private placement, Alafi Capital bought 3,529,192 shares at $0.8033 per share, for a total investment of approximately $2.8 million.

• Stake Increases to 17.1%

  After the transaction, Alafi Capital holds 5,242,996 shares—17.1% of the outstanding total—including 130,651 warrants at $7.15, cementing its position as a major shareholder.

• Warrants to Purchase 7.1M Additional Shares

  Subject to stockholder approval, Alafi Capital will receive Series A and Series B warrants to purchase 3,529,192 shares each (7,058,384 total), exercisable at $0.8033 and $1.00, respectively.

• Part of Broader $49M Financing

  This investment is part of the private placement announced on June 24, which raised $15 million upfront and could reach up to $49 million if warrants are exercised.

auto_awesomeAnalysis · CALC · Life Sciences

In CalciMedica's recently closed private placement, venture capital firm Alafi Capital Company LLC—managed by Christopher D. Alafi—acquired 3,529,192 shares at $0.8033 apiece, investing roughly $2.8 million. The purchase pushes Alafi Capital's total holdings to 5,242,996 shares, or 17.1% of the company, including 130,651 warrants with a $7.15 exercise price. This allocation is part of the up to $49 million financing unveiled on June 24, which delivered $15 million upfront. Coming on the heels of other insider purchases in recent weeks, Alafi Capital's participation signals robust institutional conviction in the company's outlook following positive Phase 2b data and a profitable first quarter of 2026. While the $0.8033 purchase price represents a slight discount to the current $0.93 stock price, the overall financing was structured at a premium to market when announced. The filing also reveals that, upon stockholder approval, Alafi Capital will receive Series A and Series B warrants to buy an additional 7,058,384 shares, which could further expand its stake. Such concentrated ownership by a long-term venture investor reduces the float and aligns interests with shareholders, though the potential warrant exercise introduces future dilution.